This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UniQure (QURE) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals
4 Biotechs That Could Be Potential Acquisition Targets in 2021
by Zacks Equity Research
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate
by Zacks Equity Research
Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -171.18% and -98.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for uniQure (QURE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.
BioMarin Down on CRL From FDA for Hemophilia A Candidate
by Zacks Equity Research
BioMarin (BMRN) suffers a setback as the FDA issues a CRL to its BLA for the gene therapy Roctavian, developed to treat patients with severe hemophilia A. Shares fall as a result.
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -100.00% and -91.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea (AKCA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.
Moving Average Crossover Alert: uniQure
by Zacks Equity Research
uniQure N.V. (QURE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 26.74% and -94.09%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: uniQure (QURE) Q1 Earnings Expected to Decline
by Zacks Equity Research
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -24.36% and 49.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for uniQure (QURE)
by Zacks Equity Research
uniQure (QURE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A
by Zacks Equity Research
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
5 Biotech Stocks That Have More Than Doubled This Year
by Ekta Bagri
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
Will uniQure Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in uniQure.
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
by Ekta Bagri
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Gene Therapy the Next Best Thing: Here's Why (Revised)
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Gene Therapy the Next Best Thing: Here's Why
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.